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Background: Primary care is well positioned to facilitate cardiovas-
cular risk improvement and reduce future cardiovascular disease
(CVD) burden.
Methods: The efﬁcacy of risk factor screening, behavioural counsel-
ling, and pharmacological treatment to lower CVD risk was assessed
via a prospective pre- and postintervention health risk assessment,
individualized intervention with behaviour modiﬁcation, risk factor
treatment, and linkage to community programs, with 1-year follow-up
and ﬁnal health risk assessment. Primary outcome was the proportion
of subjects with moderate and high baseline Framingham Risk Score
(FRS) reducing their risk by 10% and 25%, respectively; the secondary
end point was the proportion dropping  1 risk category.
Results: Patients were enrolled (N ¼ 1509) from March 2006 through
October 2008 and 72% completed the study. This analysis focuses on
563 subjects with moderate or high baseline FRS, and excluded 325
low-risk patients and 205 with established CVD or diabetes mellitus.
Median age was 56 years, 57.7% were female. The primary outcome
was achieved in 31.8% (N ¼ 112; 95% conﬁdence interval [CI], 26.9%-
36.6%) of moderate risk FRS participants and 47.9% (N ¼ 101; 95%Received for publication December 27, 2012. Accepted March 14, 2013.
Corresponding author: Dr Jafna L. Cox, Division of Cardiology, QEII
Health Sciences Centre, NHI Site, Room 2147, 1796 Summer St, Halifax,
Nova Scotia B3H 3A7, Canada. Tel.: þ1-902-473-7811; fax: þ1-902-473-
8616.
E-mail: jafna.cox@dal.ca
See page 1406 for disclosure information.
0828-282X/$ - see front matter  2013 Canadian Cardiovascular Society. Publishe
http://dx.doi.org/10.1016/j.cjca.2013.03.007RESUME
Introduction : Les soins primaires sont bien places pour faciliter
l’amelioration du risque cardiovasculaire et reduire le fardeau futur de
la maladie cardiovasculaire (MCV).
Methodes : L’efﬁcacite du depistage du facteur de risque, du coun-
selling comportemental et du traitement pharmacologique pour
diminuer le risque de MCV a ete mesuree par une evaluation
prospective du risque pour la sante avant et après l’intervention, l’in-
tervention individualisee axee sur la modiﬁcation du comportement, le
traitement du facteur de risque et le lien avec les programmes com-
munautaires, tout en effectuant un suivi de 1 an et une evaluation
ﬁnale du risque pour la sante. Le critère de jugement principal a ete la
proportion de sujets qui avaient un score de risque de Framingham
(SRF) initial modere ou eleve reduisant respectivement leur risque de
10 % et 25 %; le critère de jugement secondaire a ete la proportion
passant dans une categorie de risques  1.
Resultats : Les patients ont ete inscrits (N ¼ 1509) de mars 2006 à
octobre 2008, et 72 % ont mene l’etude à terme. Cette analyse met
l’accent sur 563 sujets ayant un SRF initial modere ou eleve, et a exclu
325 patients exposes à un risque faible et 205 patients ayant une MCVDespite improvements in outcomes over the past half-century, Nine traditional modiﬁable factorsdsmoking, hyperten-
cardiovascular disease (CVD) remains the major cause of global
mortality.1 Further, the societal burden of CVD is predicted to
increase because of factors such as an aging population,2 greater
therapeutic success resulting in more patients surviving cardiac
events and requiring ongoing management,3 along with rising
prevalence of CVD risk factors predicted to engender more
manifest illness2,4,5 (Supplemental References S1-S3).sion, diabetes, abnormal cholesterol proﬁle, being overweight,
having a poor diet, and physical inactivitydhave been
implicated in explaining more than 90% of the population
attributable risk for premature CVD.6 Focused attention on
interventions to address these risk factors can be expected to
reduce CVD prevalence. Although well placed to facilitate
CVD risk reduction, primary care physicians face challenges
in providing preventive health interventions, including lack of
time to screen and counsel patients.7
Multidisciplinary teams have the potential to facilitate more
effective assessment and management of risk factors in primary
care. The “A Novel Approach to Cardiovascular Health By
Optimizing Risk Management” study (ANCHOR) used
nurses, dieticians, pharmacists, social workers, psychologists,
and physiotherapists, as needed, to deliver cardiovasculard by Elsevier Inc. All rights reserved.
CI, 41.2%-54.6%) of high-risk participants. The secondary outcome
was achieved by 37.2% (N ¼ 210; 95% CI, 33.2%-41.2%). Prevalence
of metabolic syndrome fell from 79.2% (N ¼ 446; 95% CI, 75.9%-
82.6%) at entry to 52.8% (N ¼ 303; 95% CI, 48.7%-56.9%) at study
end. Signiﬁcant improvements in all modiﬁable risk factors occurred
through lifestyle modiﬁcation.
Conclusions: Global cardiovascular risk can be effectively decreased
via lifestyle changes informed by readiness to change assessment and
individualized counselling targeting speciﬁc behaviours. Trial registra-
tion: ClinicalTrials.gov number NCT01620996.
ou un diabète sucre etabli. L’âge median etait de 56 ans, 57,7 %
etaient de sexe feminin. Le critère de jugement a ete atteint chez
31,8 % (N ¼ 112; intervalle de conﬁance [IC] à 95 %, 26,9 %-36,6 %)
des participants ayant un SRF modere et 47,9 % (N ¼ 101; IC à 95 %,
41,2 %-54,6 %) des participants exposes à un risque eleve. Le critère
de jugement secondaire a ete atteint par 37,2 % (N ¼ 210; IC à 95 %,
33,2 %-41,2 %). La prevalence du syndrome metabolique est passee
de 79,2 % (N ¼ 446; IC à 95 %, 75,9 %-82,6 %) au debut à 52,8 %
(N ¼ 303; IC à 95 %, 48,7 %-56,9 %) à la ﬁn de l’etude. Des
ameliorations signiﬁcatives de tous les facteurs de risque modiﬁables
sont apparues en changeant le mode de vie.
Conclusions : Le risque cardiovasculaire global peut être efﬁcacement
diminue par des changements dans le mode de vie en agissant sur
l’engagement à changer l’evaluation et le counselling qui ciblent des
comportements speciﬁques. Enregistrement des essais cliniques :
ClinicalTrials.gov, numero NCT01620996.
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grated within primary health care centres, and aimed to deter-
mine whether such an approach would result in important
reductions in global CVD risk among exposed patients.Methods
Study design
The ANCHOR study design, oversight, and methodology
have been published.8 The Ethics Review Boards of the Capital
District Health and Cape Breton District Health Authorities
in Nova Scotia approved the protocol. Brieﬂy, ANCHOR used
a nonrandomized prospective pre- and postintervention design
and a common method of evaluating behavioural and lifestyle
interventions.9 Two large primary care practices in Nova
Scotia, reﬂecting 2 distinct geographic locations and 2 different
physician reimbursement models (fee for service and alterna-
tive funding plan), participated as active intervention sites. A
comparison group from a separate primary care practice was
recruited with the intent of discerning any Hawthorne effect
from administering a health risk assessment (HRA).
Study population
At study entry, eligible and consenting participants
completed a validated and widely applied HRA (Coronary Risk
Proﬁle; Wellsource Inc, Portland, OR10), and a readiness to
change and goal setting assessment. The HRA provided 2
metrics: an individual Framingham Risk Score (FRS), a 10-year
risk estimate (interval level data) of a major cardiovascular event
(cardiovascular death, nonfatal myocardial infarction, or
stroke); and a risk categorization (nominal level data) of either
low (< 10% FRS), moderate (10%-20% FRS), or high risk
(> 20% FRS, or diabetes mellitus or any atherosclerotic
disease), based on the National Cholesterol Education Program
guidelines, Adult Treatment Panel 3 (NCEP-ATP III).
Consistent with current Canadian prevention guidelines,11
participants were categorized into low, moderate, or high-risk
cohorts after 2 additional adjustments. The FRS was multi-
plied by 2 for a family history of premature CVD11 (Supple-
mental References S5 and S6). Participants were additionally
classiﬁed as having metabolic syndrome (MS) if they satisﬁed 3of the 5 National Heart, Lung and Blood Institute criteria for
this diagnosis. Such individuals were moved up a risk category,
as has been suggested, to recognize their greater hazard.11,12
Though MS presence could inﬂuence risk category change,
the absence of any validated weighting algorithm for MS in the
literature meant that FRS scores remained unadjusted for this
condition.
Study intervention
The cornerstone of ANCHOR was a behaviour change
counselling approach to risk reduction via lifestyle change
that employed operationalized interventions for motivational
enhancement, behaviour modiﬁcation, and emotion manage-
ment.13,14 The ANCHOR intervention was tailored accord-
ing to the participants’ needs, modulated by risk status and
readiness to change. Whenever possible, patients were referred
to existing community resources. Additionally, adherence to
medication for managing cardiovascular risks, current or
subsequent, was considered a nonnegotiable behavioural goal.
Adequate follow-up is 1 of the keys to the success of CVD risk
reduction programs, yet a gold standard has not been iden-
tiﬁed. Considering that studies reporting visits of once every
2 months more commonly reported success in CVD risk
reduction,14 6 face-to-face interventions were arranged over
the course of 12 months for those in the moderate and high-
risk categories.
Clinicians delivering the intervention were trained in the
principles of motivational interviewing and readiness assess-
ment by clinical health psychologists through iterative
competency-based feedback. Initial visits involved assessing and
reviewing the participant’s cardiovascular risk and establishing
initial behavioural goals. Follow-up involved speciﬁc interven-
tions to maintain motivation (such as decisional balance and
self-efﬁcacy enhancement), achieve behaviour change (goal
setting, behaviour shaping, stimulus control), and manage
emotional issues (support enhancement, stress management).
Outcomes
Differences in clinical parameters from pre- to post-
intervention were analyzed across the entire study population.
Because the primary interest of the study was primary
prevention, this analysis focused on participants, categorized
1402 Canadian Journal of Cardiology
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risk Framingham categories without established atherosclerosis
or diabetes (considered a “coronary disease equivalent”). In
this cohort, the targeted primary outcome was the proportion
of participants in the moderate and high FRS strata reducing
their risk of a coronary event by 10% and 25%, respectively,
from pre- to postintervention. The secondary outcome of
interest was the proportion of participants in the moderate or
high FRS categories dropping at least 1 risk category from pre-
to postintervention. Changes in modiﬁable risk factors,
irrespective of baseline risk or presence of established disease,
changes in drug utilization from pre- to postintervention,
differences in outcomes between the 2 primary care practices,
and the proportion of participants meeting criteria for MS
at study entry compared with postintervention were also
analyzed.
Statistical analyses
Sample size calculations8 determined that 285 participants
in each of the moderate and high FRS categories would
provide a power of 80% with an a of 0.05 to show the
primary study outcome goal. Population risk proﬁles
described in the Nova Scotia Health Survey 199515 suggested
enrollment of 1500 participants would yield a primary
prevention cohort of 570 moderate- or high-risk individuals.
Changes in clinical variables and drug use pre- and post-
intervention were assessed using paired t tests for continuous
variables and c2 analysis for categorical variables. The
percentage and 95% conﬁdence interval (CI) of patients
meeting targets, and of patients initially classiﬁed with MS
who subsequently failed to meet criteria, were calculated.
Comparisons between groups were made using c2 analysis for
categorical data and independent t tests for continuous vari-
ables. Analyses were performed using PASW version 18
(SPSS/IBM, Chicago, IL).Figure 1. Participant ﬂow. Note that patients in the comparison cohort ultim
cohort so as to preclude comparison and, as such, were not included in any d
Optimizing Risk Management; CVD, cardiovascular disease; DM, diabetes mResults
Overall study sample and patient characteristics
From March 2006 through October 2008, a total of 1509
participants were recruited into the intervention arm of the
ANCHOR study, and 215 were screened for inclusion in the
comparison arm (Fig. 1). Data were analyzed beginning in 2011.
There were 416 patients (27.6%) who withdrew from the
intervention arm of the study. Compared with those who
completed the study, individuals who withdrew were younger,
more likely female, hadhigherweight andbodymass index, larger
waist circumference, lower systolic bloodpressure, andweremore
likely to be smokers (Table 1). Of 119 patients initially enrolled
into the comparison group who had a baseline and follow-up
HRA, 27 withdrew (22.7%). The ﬁnal cohort differed signiﬁ-
cantly from the intervention group across several important
demographic and clinical variables (Table 1). Because these
differences precluded meaningful comparisons, the comparison
group was not considered in subsequent analyses.Primary prevention cohort
Of the patients who completed the intervention, 563 were
at either medium or high baseline cardiovascular risk and did
not have established disease; they became the primary
prevention cohort and the central focus of the current study.
The median age was 56 years and 57.7% were women. The
mean and median FRS scores were 10.8% and 8.0%,
respectively. Other modiﬁable baseline characteristics are
shown in Table 2. Considering that a participant’s category
could be switched on the basis of the development or loss of
the MS, it is important to note that 446 (79.2%) participants
met criteria for MS at baseline.ately differed sufﬁciently at baseline from patients in the intervention
ata analysis. ANCHOR, A Novel Approach to Cardiovascular Health By
ellitus; FRS, Framingham Risk Score; HRA, health risk assessment.
Table 1. ANCHOR participants: baseline characteristics




P*Completed (N ¼ 1093) Withdrew (N ¼ 416) Completed (n ¼ 92)
Female (%) 66 64.5 70.7 0.02 46.7 < 0.01
Age (y) 53.76 (11.48) 55.13 (11.33) 50.17 (11.08) < 0.01 59.62 (5.85) < 0.01
Weight (kg) 89.35 (20.8) 87.4 (19.85) 94.51 (22.33) < 0.01 92.57 (22.33) 0.02
BMI 32.39 (6.94) 31.64 (6.56) 34.37 (7.49) < 0.01 32.49 (5.54) 0.23
Waist circumference (cm)y 104.15 (15.91) 102.59 (15.22) 108.25 (16.95) < 0.01 104.54 (12.93) 0.23
Total cholesterol (mmol/L)z 5.04 (1.12) 5.05 (1.09) 5.02 (1.21) 0.58 5.16 (1.07) 0.38
LDL (mmol/L) 3.02 (1.34) 3.02 (0.99) 3.03 (1.97) 0.82 2.98 (1.05) 0.76
HDL (mmol/L)y,z 1.21 (0.39) 1.22 (0.38) 1.20 (0.40) 0.35 1.28 (0.42) 0.17
Triglycerides (mmol/L)y 1.84 (1.13) 1.81 (1.10) 1.92 (1.21) 0.11 2.10 (1.47) 0.02
Systolic BP (mm Hg)y,z 128.44 (18.04) 129.04 (17.84) 126.88 (18.48) 0.04 133.86 (15.25) 0.01
Diastolic BP (mm Hg)y 79.94 (10.50) 79.89 (10.44) 80.07 (10.68) 0.77 78.14 (10.55) 0.12
Blood glucose (mmol/L)y 5.88 (1.44) 5.85 (1.36) 5.95 (1.63) 0.22 5.62 (0.69) 0.01
FRS 14.29 (9.67) 8.8 (10.49) 6.80 (9.28) < 0.01 12.23 (10.88) 0.10
Current smoker (%) 15.6 13.0 22.3 < 0.01 16.3 0.37
Data are presented as mean (SD), except where otherwise speciﬁed.
ANCHOR, A Novel Approach to CardiovascularHealth ByOptimizing Risk Management; BMI, body mass index; BP, blood pressure; FRS, Framingham Risk
Score; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
yVariables contributing to the diagnosis of metabolic syndrome.
zVariables contributing to Framingham Risk Score (FRS).
* Completed intervention vs comparison group.
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The targeted reduction in risk was achieved in 31.8%
(95% CI, 26.9%-36.6%) of participants in the moderate
category and 47.9% (95% CI, 41.2%-54.6%) of participants
in the high category.
FRS category shift in the primary prevention cohort
Though risk category improvement was seen across the entire
ANCHOR population (Fig. 2), it was particularly notable in the
primary prevention cohort in which 37.2% (95% CI, 33.2%-
41.2%) of participants shifted to a lower risk category (Fig. 3).
Further, as Figure 3 shows, 9.5%of participants (95%CI, 7.1%-
11.9%) shifted risk down 2 categories, from high to low.
However, 56.5% of participants (95% CI, 52.4%-60.6%)
remained in the same category and 9.9% of participants (95%
CI, 7.4%-12.4%) moved to a higher risk category.
Additional analyses
Signiﬁcant pre- and postintervention changes were noted
across all clinical variables of interest in the primary preventionTable 2. Pre- to postintervention change in modiﬁable risk factors in the pr
Risk Factor Preintervention Po
Weight (kg) 90.64 (18.98) 8
BMI 32.37 (6.36) 3
Waist circumference (cm)* 105.45 (13.64) 10
Total cholesterol (mmol/L)y 5.25 (1.06)
LDL (mmol/L) 3.21 (0.96)
HDL (mmol/L)*,y 1.11 (0.32)
Triglycerides (mmol/L)* 2.06 (1.21)
Systolic BP (mm Hg)*,y 133.62 (17.17) 12
Diastolic BP (mm Hg)* 82.72 (10.38) 7
Blood glucose (mmol/L)* 5.73 (0.88)
FRS 10.82 (10.55)
Current smoker (%) 17
Data are presented as mean (SD), except where otherwise speciﬁed.
BMI, body mass index; BP, blood pressure; FRS, Framingham Risk Score; HD
*Variables contributing to the diagnosis of metabolic syndrome.
yVariables contributing to Framingham Risk Score (FRS).cohort (Table 2). Importantly, these improvements were seen in
the absence of any signiﬁcant change in the use of risk-
modifying drugs from pre- to postintervention, with the sole
exception of statins (Supplemental Table S1). Changes in
modiﬁable risk factors over the course of ANCHOR were
similarly analyzed in the low risk category at baseline and the
secondary prevention cohort (patients with established CVD or
diabetes mellitus) (Supplemental Table S2). In the low risk
group, there was little change in blood pressure or lipid proﬁle,
but nonetheless there were signiﬁcant reductions in weight,
body mass index, waist circumference, and blood glucose levels
postintervention. Despite this, there was a slight increase in
FRS, potentially because of increases in age and low-density
lipoprotein cholesterol levels. Those in the secondary preven-
tion cohort demonstrated signiﬁcant improvements across all
modiﬁable risk factors other than triglycerides.
The ANCHOR intervention was conducted in 2 family
practice settings that differed by geographical region and
remuneration pattern, and no signiﬁcant differences were noted
across sites. Meeting the target FRS reduction was achieved by
37.7% (95%CI, 31.2%-44.2%) inHalifax vs 37.9% (95%CI,imary prevention cohort (N ¼ 563)
stintervention P Mean change (%)
8.52 (18.70) < 0.01 2.3
1.71 (6.53) < 0.01 2.0
2.01 (13.13) < 0.01 3.3
5.05 (1.12) < 0.01 3.8
3.03 (1) < 0.01 5.6
1.17 (0.33) < 0.01 5.4
1.89 (1.06) < 0.01 8.2
7.60 (15.12) < 0.01 4.5
8.95 (9.38) < 0.01 4.6
5.45 (0.78) < 0.01 4.9
9.30 (9.58) < 0.01 14
13 < 0.01 23.5
L, high-density lipoprotein; LDL, low-density lipoprotein.
Figure 2. Shift in Framingham risk category preintervention vs postintervention in the overall study sample (N ¼ 1093).
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by 36.8% (95% CI, 30.3%-43.3%) in Halifax and 37.6%
(95% CI, 31.1%-44.1%) in Sydney (P ¼ 0.87).
Finally, the number of participants meeting criteria for MS
shifted from 79.2% (95% CI, 75.9%-82.6%) at entry to
52.8% (95% CI, 48.7%-56.9%) at study end.Discussion
The ANCHOR study showed that a behavioural and
pharmacological intervention in multidisciplinary primary
care settings, whose intensity was weighted according to
clinical risk and readiness to change, could reduce cardiovas-
cular risk. Signiﬁcant improvements were seen across virtually
all modiﬁable clinical parameters in all study groups. ThoughFigure 3. Shift in Framingham risk category preintervention vs pothis was especially consistent in the primary prevention
cohort, patients entering the study at low risk were largely
maintained in that category and many with established disease
had their risk proﬁles ameliorated.
Achieving such demonstrable success in a multidisciplinary
primary care environment, the current strategy ofmuch primary
health care reform, is novel and important for several reasons.
Though physician knowledge is generally high regarding the
consequences of risk factors and the beneﬁt of their treatment,
use of preventive interventions and risk behaviour counselling
is consistently less than recommended.16 Notwithstanding
accepted guidelines, clinical trial evidence of beneﬁt, and
favourable cost-effectiveness studies, less than half of patients
have their risk factors reliably assessed, treated, or controlled,
a disparity that applies equally to primary and secondarystintervention in the primary prevention cohort (N ¼ 563).
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risk factors will beneﬁt, lifestyle needs to be addressed. Physical
inactivity increases the risk of many major noncommunicable
diseases, including obesity and diabetes, and by itself accounts
for 9% of premature mortality worldwide.17
The gap between knowledge and management is particularly
wide around behavioural interventions, which might relate to
implementation challenges or uncertainty as to the most
effective approach. Previous studies demonstrated only
a modest effect of primary prevention interventions on risk
factors and none on mortality.18 More recent efforts,19,20
(Supplemental References S7-S9) targeting speciﬁc patient
subgroups (mostly overweight) have resulted in improvements
in risk factor proﬁles, but required costly and intense inter-
ventions, including supervised exercise. Workplace programs
focused on reducing cardiovascular risk have also demonstrated
modest beneﬁts, though individuals tend to regress quickly after
the intervention.21,22 Community-based cardiovascular
programs offer potential for risk reduction, but dropout rates
are high23 and the effect sizes modest.24
Few studies report the effect of such programs in primary
care,25,26 and these have focused on secondary rather than
primary prevention. Most advanced health care systems are
investing in primary care, establishing it as the “medical
home”27 for patients and a ready access point to chronic
disease management, with referral as necessary to acute
specialty care and other services. Primary care offers a poten-
tially universal portal to provide risk factor screening, ongoing
surveillance and treatment, and continued education and
messaging on lifestyle change. ANCHOR applied theory-
driven, evidence-based strategies to support behaviour
change and has proven these are effective.
Behavioural drift and persistence with treatment, especially
lifestyle change, are well documented problems.28 Only half of
patients might adhere to long-term drug regimens, and the
percentage complying with medical advice is even lower.29
Even when good dietary and exercise habits are apparently
maintained, risk parameters might worsen.30 Nonetheless, it is
possible to maintain gains with appropriate reinforcement31
and an ongoing ANCHOR substudy is addressing this.
Of interest, despite the focus on behaviour change using
evidence-based principles, not all patients were equally likely
to be engaged; and individuals who withdrew from the study
differed signiﬁcantly across several demographic and clinical
variables from those who stayed. They were more likely to be
a current smoker, female, younger, more obese, and have
greater waist circumference. We are also further studying this
subgroup in which motivational interviewing before behav-
iour change interventions might potentially beneﬁt.
The reduction in the prevalence of MS was an especially
noteworthy ﬁnding and appears to have been achieved
primarily through the effect of behavioural counselling
because, apart from lipid-lowering medication, no signiﬁcant
change in drug prescribing occurred over the course of the
study. MS is a major precursor to diabetes and there is
accumulating evidence that its presence has incremental
prognostic effect beyond its risk factor components.32 Thus,
reducing MS can be expected to result in greater improvement
in clinical outcomes than would be predicted on the basis of
change in FRS alone. This study demonstrates potential to
improve the MS proﬁle even for patients with establisheddisease or those with otherwise low FRS, a ﬁnding of parti-
cular importance to this latter group who typically are at lower
priority for intervention and yet might be carrying a greater
risk burden, especially in terms of future events, than what
conventional risk scores are able to predict.33
Tools such as the FRS are accurate and useful in estimating
risk at the individual and population levels and are the
accepted foundation for prevention strategies34 (Supplemental
References S11, S12). They are especially effective in assessing
the beneﬁt of interventions that simultaneously target several
cardiovascular risk factors and recent prevention guidelines
advocate speciﬁcally for universal risk assessment.35 Impor-
tantly, risk factor burden has been clearly correlated with
outcomes over the short and long term with substantial
clinical and economic beneﬁts to be realized from its
improvement36 (Supplemental Reference S13).
Limitations
The ANCHOR study was not without limitations. First,
a traditional randomized controlled trial design was not adopted
and the lack of randomization potentially limits the estimate of
treatment effect. But, as compellingly argued in a recent article,
such a methodological approach, however much considered the
“gold standard,” might be inadequate to assess the “complex
problems of complex patients embedded in complex healthcare
systems in complex and changing communities that require
complex interventions embedded in changing socioeconomic-
political conditions and health policies.”37 Thus, observational
epidemiology is an acceptedmeans of evaluating behavioural and
lifestyle interventions.9 Indeed, this representative design
enhanced generalizability and the usual myriad of exclusion
criteria in a traditional randomized controlled trial were absent; it
allowed behavioural goals to be tailored to the needs of individual
participants; patients were not “administered” treatment but
rather educated aboutmaking the right choices regarding lifestyle
and management; and although study staff were equally trained
in behavioural techniques, their professional backgrounds were
not stipulated.Collectively, this allowed us tomimic how such an
intervention would occur in the “real world.”
A second potential limitation was that the intervention and
comparison groups were sufﬁciently different to preclude the
intended assessment of the speciﬁc effect of the HRA.
However, data published subsequent to the launch of the
ANCHOR study provided no compelling evidence that
presentation of an HRA to patients, by itself, results in
improved health outcomes.38
Conclusion
ANCHOR demonstrated that cardiac risk could be
successfully reduced in the primary care setting among
patients without manifest CVD by applying a comprehensive
program encompassing behavioural intervention of varying
intensity according to patient risk, setting goals based on risk
factors and readiness to change, nonnegotiable medication
adherence, and referral to existing community resources to
support lifestyle change. The improvements were largely
realized through lifestyle modiﬁcation rather than increased
medication and the effect seems to be independent of primary
care organization or reimbursement model. Considering that
the resources and skills applied through ANCHOR are readily
1406 Canadian Journal of Cardiology
Volume 29 2013imported into any practice type, the approach is likely
portable to other health care jurisdictions or systems. Ongoing
research is focused on long-term effect, treatment of nonre-
sponders, and cost effectiveness.Disclosures
Please see Supplemental Appendix S1 for Acknowledge-
ments, Role of Study Sponsor, and Conﬂict of Interest
Declarations.
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